Results 21 to 30 of about 5,265 (145)

Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C [PDF]

, 2016
Sofosbuvir and simeprevir are used for the treatment of chronic hepatitis C (HCV) genotype 1. Both drugs have been well-tolerated, with diarrhea noted in 6% cases with sofosbuvir, 16% with sofosbuvir plus simeprevir, and 0% with simeprevir.
Mitchell, Kisha A, Jakab, Simona, Oikonomou, Ioannis, Lim, Joseph K, Sarkar, Souvik   +4 more
core   +1 more source

Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. [PDF]

PLoS ONE, 2018
Thailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care's benefit package.
Waranya Rattanavipapong, Thunyarat Anothaisintawee, Yot Teerawattananon   +2 more
doaj   +1 more source

Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents

BMC Infectious Diseases, 2019
Background Sofosbuvir is the keystone of direct antiviral agents for the chronic hepatitis C (CHC). The safety of sofosbuvir in patients with stage 4–5 chronic kidney disease (CKD) needs further observation in real world.
Taotao Yan, Jiuping Wang, Juan Li, Shan Fu, Yi Chen, Chunhua Hu, Rou Zhang, Zhen Tian, Fahui Zhao, Jun Dong, Jinfeng Liu, Yuan Yang, Tianyan Chen, Yingren Zhao, Yingli He   +14 more
doaj   +1 more source

Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients

Journal of Transplantation, 2018
Background. Since the introduction of direct antiviral agents (DAAs), morbidity of HCV has considerably decreased but still no guidelines have been formulated in renal transplant recipients (RTRs). We studied efficacy and tolerability of direct antiviral
Sourabh Sharma, Debabrata Mukherjee, Ranjith K. Nair, Bhaskar Datt, Ananth Rao   +4 more
doaj   +1 more source

The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.

PLoS ONE, 2021
BackgroundDirect-acting antiviral (DAA) drugs have been effective in the treatment of chronic hepatitis C virus (HCV) infection. Limited data are available on safety, tolerability, and efficacy in American Indian or Alaska Native people.
Lisa Townshend-Bulson, Elena Roik, Youssef Barbour, Dana J T Bruden, Chriss E Homan, Hannah G F Espera, Timothy J Stevenson, Annette M Hewitt, Wileina Rhodes, James E Gove, Julia N Plotnik, Mary M Snowball, John McGilvray, Brenna C Simons, Janet M Johnston, Brian J McMahon   +15 more
doaj   +1 more source

Co-crystallization of Sofosbuvir with Sugars for Enhanced Dissolution Rate [PDF]

, 2023
Sofosbuvir is one of the direct acting antiviral agents which is approved in the treatment of chronic HCV in combination with other agents. The low aqueous solubility of sofosbuvir resulted in slow dissolution which is supposed to be responsible for its ...
El Maghraby, Gamal Mohamed, Mousa, Taher Mohamed Yassen, Donia, Ahmed Atef   +2 more
core   +1 more source

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection [PDF]

, 2015
BACKGROUND: In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C ...
Ruane, Peter, Agarwal, Kosh, Osinusi, Anu, Han, Lingling, Thompson, Alex, Mo, Hongmei, Afdhal, Nezam, Towner, William J, McHutchison, John G, Roberts, Stuart K, Patel, Keyur, Cooper, Curtis, Dvory-Sobol, Hadas, Mazzotta, Francesco, Rosenberg, William, Lawitz, Eric, Mangia, Alessandra, Tran, Tram T, Conway, Brian, McNally, John, Gane, Edward J, Shiffman, Mitchell L, Wang, Jing, Brainard, Diana M, Reau, Nancy, Bräu, Norbert, Pianko, Stephen, Sulkowski, Mark, Foster, Graham R, Berg, Thomas, Gordon, Stuart C, Asselah, Tarik, Stedman, Catherine AM, Bourlière, Marc, Zeuzem, Stefan   +34 more
core   +1 more source

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection [PDF]

, 2014
International audienceBackgroundIn phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously ...
Crespo, F. Javier, Arora, Sanjeev, Smith, Coleman, Mchutchison, John, G., Workowski, Kimberly, Albers, Christopher, Rizzetto, Mario, Brown, Ashley, Mangia, Alessandra, Lawitz, Eric, Morgan, Timothy R, Andreone, Pietro, Ratziu, Vlad, Poleynard, Gary, Flamm, Steven, Reindollar, Robert, Sulkowski, Mark, Buggisch, Peter, Elion, Richard, Everson, Gregory, Bourlière, Marc, Ravendhran, Natarajan, Angelico, Mario, Cramp, Matthew, Saag, Michael, S., Poterucha, John, Bronowicki, Jean-Pierre, Yang, Jenny, Reddy, K. Rajender, Mchutchison, John,, Thimme, Robert, Pruitt, Ronald, Gerken, Guido, Nahass, Ronald, Cooper, James, Pang, Phillip, Rustgi, Vinod, Kugelmas, Marcelo, Poulos, John, García-Samaniego, Javier, Craxi, Antonio, Gordon, Stuart, Jacobson, Ira, Jeffer, Lennox, Colombo, Massimo, Freilich, Bradley, Berg, Thomas, Kwo, Paul, Puoti, Massimo, Dusheiko, Geoffrey, Romero-Gomez, Manuel, Zeuzem, Stefan, Ruane, Peter, Lohse, Ansgar, Saag, Michael,, Fried, Michael, Younes, Ziad, Muir, Andrew, J., Patel, Keyur, Serfaty, Lawrence, Chung, Raymond, Chojkier, Mario, Brown Jr., Robert, Muir, Andrew,, Goeser, Tobias, Ryan, Michael, Foster, Graham, Schiff, Eugene, Symonds, William, Hinestrosa, Federico, Ghalib, Reem, Lee, William, Bräu, Norbert, Bennett, Michael,, Shiffman, Mitchell,, Gitlin, Norman, Bennett, Michael, A., Hezode, Christophe, Rodriguez-Torres, Maribel, Agarwal, Kosh, Pound, David, Nelson, David, Rossaro, Lorenzo, Davis, Mitchell, Buti, Maria, Alberti, Alfredo, Bernstein, David, Andrade, Raúl, Mo, Hongmei, Afdhal, Nezam, Mutimer, David, Han, Steven-Huy, Mauss, Stefan, Hawkins, Trevor, Subramanian, G. Mani, Marcellin, Patrick, Ustianowski, Andrew, Di Bisceglie, Adrian, Dretler, Robin, Shiffman, Mitchell, L., Beavers, Kimberly, Ding, Xiao, Galati, Joseph, Pockros, Paul, Sheikh, Aasim, Wedemeyer, Hans, Kowdley, Kris V, Zarski, Jean-Pierre, Nguyen, Mindie, Forns, Xavier, Herring, Robert, Gallert, Peter   +111 more
core   +2 more sources

Medicament testing on acupuncture points as a non-invasive diagnostic tool for determining the daily doses of sofosbuvir in patients with chronic hepatitis C virus infection

Future Journal of Pharmaceutical Sciences, 2023
Background Acupuncture points are known for their unique bioelectric properties. Medication testing at acupuncture points has not previously been used to determine the daily doses of sofosbuvir in patients with chronic hepatitis C virus infection ...
Naylya Djumaeva, Gulnara Akhundjanova, Leyla Djumaeva, Dilbar Urunova   +3 more
doaj   +1 more source

Sustained virological response to antiviral drugs in treatment of different genotypes of HCV cirrhotic patients

Pakistan Journal of Pharmaceutical Sciences, 2023
Cirrhosis and liver cancer are both caused by hepatitis C virus (HCV) infection of the liver. Patients with HCV cirrhosis may be treated with one of many antiviral medications, depending on their specific genotype.
Amin Ullah, Aqsa Maryam, Ghaffarul Malik, Hira Hameed, Kifayat Hussain, Junaid Ahmad, Ihteshamul Haq, Mohsina Haq, Reem M Aljowaie, Elsayed Mohsen Abougazia, Tse-Wei Chen, Jamshaid Ahmad, Kashif Bashir, Laiba Ahmad, Bashir Ahmad   +14 more
doaj   +1 more source